Short answer
PROCEPT BioRobotics Corp (PRCT) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $98M (up 18.0% year over year) with net income of −$27M.
Q3 2026 key financials · XBRL
- Revenue
- $98M
- +18.0% YoY · +4.0% QoQ
- Net income
- −$27M
- −23.8% YoY · +1.3% QoQ
- Operating margin
- -27.9%
- Gross margin
- 66.3%
- EPS (diluted)
- −$0.46
- −17.9% YoY · +2.1% QoQ
Source: XBRL data from the PROCEPT BioRobotics Corp (PRCT) Q3 2026 10-Q on SEC EDGAR. USD.
PROCEPT BioRobotics Corp Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $98.3M, up 18% YoY from $83.3M
- Gross margin 66% vs 65% YoY, including $3.2M tariff refunds
- Best line handpieces and consumables $60.8M, up from $49.7M; weakest systems $29.2M vs $28.1M
- Operating cash flow $(66.4)M for nine months vs $(38.7)M; investing outflow $6.5M
- Cash $218.4M; management expects funding through at least the next twelve months, with higher sales, marketing and R&D spending ahead
Risk Factors
- No material changes to previously disclosed risk factors during nine months ended September 30, 2026
- Healthcare industry risks remain relevant to business, financial condition, and operating results
- Unknown or currently immaterial risks could materially adversely affect results
- Historical financial performance may not reliably indicate future results
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PROCEPT BioRobotics Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.